Immunotherapeutics Biotech Company Fundraising to Hire Research Team


Chemotherapy as a solution for cancer is quickly losing credibility.

According to a study in 2015 by the New England Journal of Medicine on more than 10,000 women with breast cancer, 1,626 who had the disease in an early stage with no lymph node involvement were given hormonal treatment alone.

A flurry of recent media reports says that many breast cancer survivors are dying of heart disease, partly because chemotherapy can weaken the heart muscle.

Tired of old solutions such as surgery, radiation, and chemotherapy, tBrexa is embracing the world of immunotherapeutics, a treatment that involves using certain parts of a person’s immune system to fight diseases such as cancer.

This can be done by stimulating your own immune system to work harder or smarter to attack cancer cells, or giving your immune system components such as man-made immune system proteins.

“TBrexa is working on changing the way we approach cancer, one patient at a time,” Dr. Leona Saunders, founder and CEO of the company, told The Buzz. “Engineered immunotherapies are one of the most promising frontiers in rare diseases. With tBrexa we are taking a different approach to gene cell engineering and modification. tBrexa will focus on cutting-edge research and products in life science.”

Dr. Saunders said the company, which currently works out of Mansfield Bioincubators, is in the process of negotiating the exclusive licensing of its compound so she couldn’t yet provide further details.

But according to the regulatory affairs professional, there is going to be a $30 billion immunotherapy market by 2030.

Dr. Saunders has bootstrapped the business so far with $75,000 of her own funds, but is currently in the process of applying for non-dilutive funding from the U.S. Small Business Administration, the Small Business Innovation Research program, the National Institute of Health and other Massachusetts innovation grants.

She is also in the process of speaking to potential investors and mentors.

In six months, Dr. Saunders hopes to have a full management team and research staff in place. If interested in funding tBrexa, please email


Please enter your comment!
Please enter your name here